# Excalipoint Therapeutics

Source: https://onco.cc/companies/excalipoint-therapeutics/  
OnCo record `excalipoint-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Excalipoint Therapeutics develops three-armed antibodies that attach immune T cells to solid-tumour cells and switch them on more fully. Its lead medicine, aimed at the protein DLL3 on small cell lung cancer and neuroendocrine tumours, is in an early clinical trial.

## Summary

Excalipoint Therapeutics, a Shanghai company working from the Roche Accelerator building, launched publicly on 18 March 2026 with USD 68.7 million in financing: a USD 41 million seed round completed in 2025 and a USD 27.7 million extension. Its backers include HSG, Lilly Asia Ventures and Eisai's venture arm. The lead EXP011 is a trispecific T cell engager against DLL3 plus two immune cell targets, in phase 1/2 for small cell lung cancer and neuroendocrine tumours. A second trispecific, EXP012, adds CDH17 as the tumour target. Both were licensed from Lepu Biopharma for USD 10 million upfront. Chief executive Lei Fang was previously a vice president at Lepu.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Excalipoint Therapeutics Inc.
- HQ: Shanghai
- Type: biotech
- Website: https://www.excalipoint.com/

## Notes

- The company website (read 29 October 2026) confirms only that it is a clinical-stage T-cell engager company with EXCOPIA, EXiShield and EXPROMA platforms and that EXP011 is in phase 1/2 for solid tumours; the financing, the Lepu licence and the targets come from BioPharma Dive (18 March 2026). The two immune cell targets of EXP011 were not confirmed on a page read for this record, so they are not linked. Founding in August 2025 is reported by BioCentury but not stated by the company, so founded is left blank.

## Sources

- Official website: https://www.excalipoint.com/
- BioPharma Dive: Excalipoint banks USD 69M: https://www.biopharmadive.com/news/excalipoint-biotech-startup-china-t-cell-engagers/814829/

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/), [Trispecific antibodies](https://onco.cc/technologies/trispecific-antibodies/)
- targets: [DLL3](https://onco.cc/targets/dll3/)

---
JSON: https://onco.cc/api/v1/entities/excalipoint-therapeutics.json